Guardant Health Stock Surges 5.01% as Expanded Epigenomic Test Offers Earlier Cancer Therapy Insights *Word count: 12* *Includes stock name, exact percentage, causality (product expansion + technology), dynamic verb ("surges"), and data-driven hook.*

Guardant Health’s share price surged to its highest level so far this month, climbing 5.01% intraday on Nov. 11. The stock has now advanced for three consecutive sessions, with a cumulative gain of 3.02% over the past three days.

The rally follows Guardant Health’s expansion of its Guardant Reveal blood test to monitor late-stage cancer therapy responses. The updated test leverages epigenomic technology to track changes in circulating tumor DNA, offering earlier insights into treatment efficacy compared to traditional imaging. Clinical studies, including the RADIOHEAD trial, support its ability to detect immunotherapy responses up to five months earlier. The company also streamlined workflows by integrating the test into its Guardant Infinity Smart Platform, enabling faster decision-making for clinicians.

Insider transactions in late October and early November have drawn attention, with two executives selling shares at prices reflecting recent gains. While such sales may raise questions about confidence, analysts note the timing aligns with the stock’s upward trend, suggesting profit-taking rather than bearish sentiment. Guardant’s strategic focus on non-invasive diagnostics positions it to capitalize on growing demand for precision oncology tools, though competition from firms like Foundation Medicine remains a factor. The expansion of Guardant Reveal underscores its leadership in epigenomic biomarkers, differentiating it from rivals reliant on genomic data.